{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:31:19Z","timestamp":1791250279647,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273397"],"award-info":[{"award-number":["82273397"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LMS26H160018"],"award-info":[{"award-number":["LMS26H160018"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Invasive papillary breast cancer (IPC) is a rare cancer known to have a better prognosis than other breast cancers. This study aimed to explore whether patients with early-stage IPC can benefit from chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>IPC cases diagnosed between 2003 and 2021 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan\u2013Meier method and the Cox proportional hazard model were performed to identify significant prognostic factors. To eliminate selection bias and baseline characteristics, propensity score matching (PSM) was used. The primary endpoints were overall survival (OS) and breast cancer-specific survival (BCSS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1892 patients were enrolled, and 273 pairs were screened after PSM. Multivariable analysis showed that age under 50, married status, smaller tumor size, negative lymph node (LN) status, and receipt of surgery, chemotherapy or radiotherapy were independently associated with better OS. After PSM, patients receiving chemotherapy had significantly improved OS (P\u2009=\u2009.012), while BCSS showed no significant difference (P\u2009=\u2009.099). After stratified by tumor size and LN status, chemotherapy could significantly improve the OS of patients with LN-negative IPC with tumors \u2265 2.0\u2009cm (P\u2009&amp;lt;\u2009.001). Among the patients with grade III or undifferentiated diseases, the OS of the chemotherapy group was significantly better than that of the non-chemotherapy group (P\u2009&amp;lt;\u2009.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For patients with LN-negative IPC with tumor \u2265 2.0\u2009cm and patients with grade III or undifferentiated disease, chemotherapy significantly improved OS. Future randomized controlled trials are expected to validate the results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf422","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T13:04:58Z","timestamp":1766149498000},"source":"Crossref","is-referenced-by-count":3,"title":["Chemotherapy improves survival for patients with lymph node-negative invasive papillary breast cancer with tumors \u22652 cm: a SEER population-based study"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3847-8494","authenticated-orcid":false,"given":"Yizi","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, Zhejiang 325000,","place":["China"]},{"name":"Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People\u2019s Hospital, Shenzhen University , Shenzhen, Guangdong 518035,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-0983","authenticated-orcid":false,"given":"Zhuozhao","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Computer Science, Eindhoven University of Technology , Eindhoven, AZ 5612,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, Zhejiang 325000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, Zhejiang 325000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Zheng","sequence":"additional","affiliation":[{"name":"The Operating Theater, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, Zhejiang 325000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"2026012601220872400_oyaf422-B1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/his.14091","article-title":"The 2019 world health organization classification of tumours of the breast","volume":"77","author":"Puay Hoon","year":"2020","journal-title":"Histopathology"},{"key":"2026012601220872400_oyaf422-B2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10549-010-0961-5","article-title":"Papillary carcinoma of the breast: An overview","volume":"122","author":"Pal","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"2026012601220872400_oyaf422-B3","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3390\/diagnostics13050878","article-title":"Clinicopathological and imaging features of breast papillary lesions and their association with pathologic nipple discharge","volume":"13","author":"Jeongeum","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"2026012601220872400_oyaf422-B4","first-page":"e11026","article-title":"Spectrum of papillary breast lesions according to world health organization classification of papillary neoplasms of breast","volume":"12","author":"Atif","year":"2020","journal-title":"Cureus"},{"key":"2026012601220872400_oyaf422-B5","first-page":"1991","article-title":"Comparative analysis of clinicopathologic characteristics and molecular subtypes of invasive papillary carcinoma of the breast and invasive ductal carcinoma: results from SEER database","volume":"26","author":"Chen","year":"2021","journal-title":"J BUON"},{"key":"2026012601220872400_oyaf422-B6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/1097-0142(19950101)75:1+<257::AID-CNCR2820751311>3.0.CO;2-Y","article-title":"Breast cancer","volume":"75","author":"Berg","year":"1995","journal-title":"Cancer"},{"key":"2026012601220872400_oyaf422-B7","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.molonc.2014.06.011","article-title":"Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast","volume":"8","author":"Salvatore","year":"2014","journal-title":"Mol Oncol"},{"key":"2026012601220872400_oyaf422-B8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrclinonc.2013.124","article-title":"Luminal breast cancer: From biology to treatment","volume":"10","author":"Michail","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"2026012601220872400_oyaf422-B9","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1056\/NEJMra1307118","article-title":"Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer","volume":"383","author":"Harold","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012601220872400_oyaf422-B10","first-page":"2018;2018:bcr2017222817","article-title":"Invasive papillary breast cancer with paget\u2019s disease: First reported association and literature review","author":"Geok Hoon","journal-title":"BMJ Case Rep"},{"key":"2026012601220872400_oyaf422-B11","doi-asserted-by":"crossref","first-page":"24037","DOI":"10.1038\/srep24037","article-title":"Clinicopathological characteristics and survival outcomes in invasive papillary carcinoma of the breast: A seer population-based study","volume":"6","author":"Yi-Zi","year":"2016","journal-title":"Sci Rep"},{"key":"2026012601220872400_oyaf422-B12","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3892\/ol.2024.14433","article-title":"Invasive papillary carcinoma of the breast: A case report","volume":"28","author":"Shijing","year":"2024","journal-title":"Oncol Lett"},{"key":"2026012601220872400_oyaf422-B13","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Angela","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026012601220872400_oyaf422-B14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00432-012-1302-3","article-title":"Clinicopathologic characteristics and molecular subtypes of invasive papillary carcinoma of the breast: A large case study","volume":"139","author":"Liu","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026012601220872400_oyaf422-B15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: A review","volume":"321","author":"Adrienne","year":"2019","journal-title":"JAMA"},{"key":"2026012601220872400_oyaf422-B16","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring therapies-improving the management of early breast cancer: St gallen international expert consensus on the primary therapy of early breast cancer 2015","volume":"26","author":"Coates","year":"2015","journal-title":"Ann Oncol"},{"key":"2026012601220872400_oyaf422-B17","first-page":"480","article-title":"Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer","volume":"73","author":"Huppert","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2026012601220872400_oyaf422-B18","first-page":"946","article-title":"High-risk premenopausal luminal a breast cancer patients derive no benefit from adjuvant cyclophosphamide-based chemotherapy: results from the DBCG77B clinical trial","volume":"23","author":"Torsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026012601220872400_oyaf422-B19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jss.2020.12.026","article-title":"Clinicopathologic characteristics and prognosis of invasive papillary carcinoma of the breast","volume":"261","author":"Huang","year":"2021","journal-title":"J Surg Res"},{"key":"2026012601220872400_oyaf422-B20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"William","year":"2024","journal-title":"J. Natl Compr Cancer Netw"},{"key":"2026012601220872400_oyaf422-B21","doi-asserted-by":"crossref","first-page":"1374091.","DOI":"10.3389\/fonc.2024.1374091","article-title":"Invasive papillary carcinoma of the breast","volume":"14","author":"Shijing","year":"2024","journal-title":"Front Oncol"},{"key":"2026012601220872400_oyaf422-B22","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1200\/JCO.2009.23.7610","article-title":"Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 AND NSABP B-20","volume":"28","author":"Eleftherios","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026012601220872400_oyaf422-B23","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update","volume":"40","author":"Fabrice","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026012601220872400_oyaf422-B24","first-page":"169","article-title":"Implications for breast cancer restaging based on the 8th edition AJCC staging manual","volume":"271","author":"Jennifer","year":"2018","journal-title":"Ann Surg"},{"key":"2026012601220872400_oyaf422-B25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12935-020-01171-5","article-title":"Breast cancer organoids from a patient with giant papillary carcinoma as a high-fidelity model","volume":"20","author":"Xuelu","year":"2020","journal-title":"Cancer Cell Int"},{"key":"2026012601220872400_oyaf422-B26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/his.12463","article-title":"Papillary and neuroendocrine breast lesions: The WHO stance","volume":"66","author":"Tan","year":"2015","journal-title":"Histopathology"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf422\/66107672\/oyaf422.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf422\/66107672\/oyaf422.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf422\/66107672\/oyaf422.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T06:22:18Z","timestamp":1769408538000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf422\/8402146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf422","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,22]]},"article-number":"oyaf422"}}